Faeth Therapeutics, Inc.
FTH
$32.34
$3.7913.28%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 244.37% | 455.45% | -1.52% | -27.34% | -16.55% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 253.15% | 2,245.71% | -32.31% | -37.99% | -33.14% |
| Operating Income | -253.15% | -2,245.71% | 32.31% | 37.99% | 33.14% |
| Income Before Tax | -224.29% | -2,380.13% | 39.29% | 37.01% | 30.89% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -224.29% | -2,380.13% | 39.29% | 37.01% | 30.89% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -224.29% | -2,380.13% | 39.29% | 37.01% | 30.89% |
| EBIT | -253.15% | -2,245.71% | 32.31% | 37.99% | 33.14% |
| EBITDA | -255.19% | -2,256.31% | 29.59% | 35.70% | 30.70% |
| EPS Basic | 27.54% | -2,312.12% | 39.44% | 37.20% | 31.20% |
| Normalized Basic EPS | 27.54% | -2,226.43% | 32.47% | 37.22% | 31.20% |
| EPS Diluted | 27.54% | -2,312.12% | 39.44% | 37.20% | 31.20% |
| Normalized Diluted EPS | 27.54% | -2,226.43% | 32.47% | 37.22% | 31.20% |
| Average Basic Shares Outstanding | 347.55% | 2.83% | 0.25% | 0.32% | 0.46% |
| Average Diluted Shares Outstanding | 347.55% | 2.83% | 0.25% | 0.32% | 0.46% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |